Beauty Farm Medical and Health Industry Inc. risk profile
28 Normal where most of the sector sits
Measured 1 September 2026 from XC5's filed statements. Recomputed nightly.
28 (Normal), driven by Market expectation at 86, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 86 | Acute | Stable | Drawdown from the 52-week high — 51.0% |
| Operating pressure | 25 | Normal | Easing | Costs outgrowing revenue — -3.9 percentage points |
| Cash conversion | 8 | Contained | Stable | Capital spending against operating cash — 0.07x |
| Leverage and coverage | 16 | Contained | Stable | Current ratio — 0.98x |
| Competitive position | 26 | Normal | Stable | R&D-intensity gap against peers — -27.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Beauty Farm Medical and Health Industry Inc.